100 related articles for article (PubMed ID: 21186953)
1. Response to sorafenib at a low dose in patients with radioiodine-refractory pulmonary metastases from papillary thyroid carcinoma.
Chen L; Shen Y; Luo Q; Yu Y; Lu H; Zhu R
Thyroid; 2011 Feb; 21(2):119-24. PubMed ID: 21186953
[TBL] [Abstract][Full Text] [Related]
2. Sorafenib in platinum-treated patients with extensive stage small cell lung cancer: a Southwest Oncology Group (SWOG 0435) phase II trial.
Gitlitz BJ; Moon J; Glisson BS; Reimers HJ; Bury MJ; Floyd JD; Schulz TK; Sundaram PK; Ho C; Gandara DR
J Thorac Oncol; 2010 Nov; 5(11):1835-40. PubMed ID: 20881645
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and tolerability of different starting doses of sorafenib in patients with differentiated thyroid cancer.
Dadu R; Waguespack SG; Sherman SI; Hu MI; Busaidy NL; Jimenez C; Habra MA; Ying AK; Bassett RL; Cabanillas ME
Oncologist; 2014 May; 19(5):477-82. PubMed ID: 24733667
[TBL] [Abstract][Full Text] [Related]
4. Sorafenib in metastatic thyroid cancer: a systematic review.
Thomas L; Lai SY; Dong W; Feng L; Dadu R; Regone RM; Cabanillas ME
Oncologist; 2014 Mar; 19(3):251-8. PubMed ID: 24563075
[TBL] [Abstract][Full Text] [Related]
5. Phase I and pharmacokinetic study of sorafenib, an oral multikinase inhibitor, in Japanese patients with advanced refractory solid tumors.
Minami H; Kawada K; Ebi H; Kitagawa K; Kim YI; Araki K; Mukai H; Tahara M; Nakajima H; Nakajima K
Cancer Sci; 2008 Jul; 99(7):1492-8. PubMed ID: 18477034
[TBL] [Abstract][Full Text] [Related]
6. Phase II trial of sorafenib in patients with metastatic breast cancer previously exposed to anthracyclines or taxanes: North Central Cancer Treatment Group and Mayo Clinic Trial N0336.
Moreno-Aspitia A; Morton RF; Hillman DW; Lingle WL; Rowland KM; Wiesenfeld M; Flynn PJ; Fitch TR; Perez EA
J Clin Oncol; 2009 Jan; 27(1):11-5. PubMed ID: 19047293
[TBL] [Abstract][Full Text] [Related]
7. SWOG 0514: a phase II study of sorafenib in patients with unresectable or metastatic gallbladder carcinoma and cholangiocarcinoma.
El-Khoueiry AB; Rankin CJ; Ben-Josef E; Lenz HJ; Gold PJ; Hamilton RD; Govindarajan R; Eng C; Blanke CD
Invest New Drugs; 2012 Aug; 30(4):1646-51. PubMed ID: 21748296
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of sorafenib in patients with metastatic or recurrent sarcomas.
Maki RG; D'Adamo DR; Keohan ML; Saulle M; Schuetze SM; Undevia SD; Livingston MB; Cooney MM; Hensley ML; Mita MM; Takimoto CH; Kraft AS; Elias AD; Brockstein B; Blachère NE; Edgar MA; Schwartz LH; Qin LX; Antonescu CR; Schwartz GK
J Clin Oncol; 2009 Jul; 27(19):3133-40. PubMed ID: 19451436
[TBL] [Abstract][Full Text] [Related]
9. A phase II study of sorafenib in malignant mesothelioma: results of Cancer and Leukemia Group B 30307.
Dubey S; Jänne PA; Krug L; Pang H; Wang X; Heinze R; Watt C; Crawford J; Kratzke R; Vokes E; Kindler HL
J Thorac Oncol; 2010 Oct; 5(10):1655-61. PubMed ID: 20736856
[TBL] [Abstract][Full Text] [Related]
10. Phase 2 Southwest Oncology Group-directed intergroup trial (S0505) of sorafenib in advanced soft tissue sarcomas.
von Mehren M; Rankin C; Goldblum JR; Demetri GD; Bramwell V; Ryan CW; Borden E
Cancer; 2012 Feb; 118(3):770-6. PubMed ID: 21751200
[TBL] [Abstract][Full Text] [Related]
11. Selective use of sorafenib in the treatment of thyroid cancer.
Pitoia F; Jerkovich F
Drug Des Devel Ther; 2016; 10():1119-31. PubMed ID: 27042004
[TBL] [Abstract][Full Text] [Related]
12. Targeted therapeutic approach for an anaplastic thyroid cancer in vitro and in vivo.
Stenner F; Liewen H; Zweifel M; Weber A; Tchinda J; Bode B; Samaras P; Bauer S; Knuth A; Renner C
Cancer Sci; 2008 Sep; 99(9):1847-52. PubMed ID: 18616678
[TBL] [Abstract][Full Text] [Related]
13. Lack of therapeutic effect of the histone deacetylase inhibitor vorinostat in patients with metastatic radioiodine-refractory thyroid carcinoma.
Woyach JA; Kloos RT; Ringel MD; Arbogast D; Collamore M; Zwiebel JA; Grever M; Villalona-Calero M; Shah MH
J Clin Endocrinol Metab; 2009 Jan; 94(1):164-70. PubMed ID: 18854394
[TBL] [Abstract][Full Text] [Related]
14. Response to sorafenib in a locally advanced oncocytic cell carcinoma of the thyroid.
Pereira A; Parra D; Alvarez M; Rincon O
BMJ Case Rep; 2024 Feb; 17(2):. PubMed ID: 38378588
[TBL] [Abstract][Full Text] [Related]
15. Discovery of New Anti-Cancer Agents against Patient-Derived Sorafenib-Resistant Papillary Thyroid Cancer.
Kim Y; Yun HJ; Choi KH; Kim CW; Lee JH; Weicker R; Kim SM; Park KC
Int J Mol Sci; 2023 Nov; 24(22):. PubMed ID: 38003602
[TBL] [Abstract][Full Text] [Related]
16. Hand-foot syndrome associated with use of sorafenib in a patient with papillary thyroid cancer: a case report.
Velandia-Carrillo C; Wandurraga-Sánchez E; Gómez-Abreo D
BMC Endocr Disord; 2014 Mar; 14():26. PubMed ID: 24641872
[TBL] [Abstract][Full Text] [Related]
17. Heart failure as first sign of development of cardiac metastases in a patient with diagnosis of papillary thyroid carcinoma on treatment with tyrosine-kinase inhibitors: differential diagnoses and clinical management.
Bruixola G; Segura A; Caballero J; Andrés A; Reche E; Escoín C; Díaz-Beveridge R
Case Rep Oncol; 2014 May; 7(2):591-9. PubMed ID: 25298765
[TBL] [Abstract][Full Text] [Related]
18. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial.
Brose MS; Nutting CM; Jarzab B; Elisei R; Siena S; Bastholt L; de la Fouchardiere C; Pacini F; Paschke R; Shong YK; Sherman SI; Smit JW; Chung J; Kappeler C; Peña C; Molnár I; Schlumberger MJ;
Lancet; 2014 Jul; 384(9940):319-28. PubMed ID: 24768112
[TBL] [Abstract][Full Text] [Related]
19. A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: A clinical outcomes and biomarker assessment.
Cabanillas ME; Schlumberger M; Jarzab B; Martins RG; Pacini F; Robinson B; McCaffrey JC; Shah MH; Bodenner DL; Topliss D; Andresen C; O'Brien JP; Ren M; Funahashi Y; Allison R; Elisei R; Newbold K; Licitra LF; Sherman SI; Ball DW
Cancer; 2015 Aug; 121(16):2749-56. PubMed ID: 25913680
[TBL] [Abstract][Full Text] [Related]
20. Subgroup analysis of Japanese patients in a phase 3 study of lenvatinib in radioiodine-refractory differentiated thyroid cancer.
Kiyota N; Schlumberger M; Muro K; Ando Y; Takahashi S; Kawai Y; Wirth L; Robinson B; Sherman S; Suzuki T; Fujino K; Gupta A; Hayato S; Tahara M
Cancer Sci; 2015 Dec; 106(12):1714-21. PubMed ID: 26426092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
